10 news items
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological functions such as hunger and weight regulation. It most
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
, which includes the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological functions such as hunger and weight
Analyst Expectations For Rhythm Pharmaceuticals's Future
RYTM
26 Apr 24
their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
RYTM
24 Apr 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated
ovt8hwe1jj493u5ktaiqka5pyfzqazuadl0ccmwbm3vxucqvrw3
RYTM
16 Apr 24
and discontinue setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
ifxrp0vx886a1
RYTM
10 Apr 24
Key Insights:
Action Taken: In response to dynamic market conditions and company
o21f8b3vlv7ssp9
RYTM
11 Mar 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
i3trrl658zr1icbb26l6ory
RYTM
6 Mar 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated. In Europe
90m6vfq9o9jcx1nrcgvr
RYTM
22 Feb 24
to the hypothalamic region of the brain, which includes the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological
- Prev
- 1
- Next